Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent model.
Saniona AB has reported that it has selected SAN-2355 as the first clinical candidate from its Kv7 epilepsy program and is poised to advance it into preclinical development.
Saniona AB has initiated the candidate selection phase with a proprietary subtype selective frontrunner molecule from its Kv7 lead optimization program for epilepsy.
Saniona AB has established a new research collaboration with Astronautx Ltd. in Alzheimer’s disease. The aim of the collaboration is to identify new treatments for Alzheimer’s disease and other neurodegenerative conditions by modulating a novel, undisclosed ion channel target. The research collaboration will use Saniona’s proprietary platform, Ionbase, for the modulation of ion channels.
Saniona AB has completed preclinical development with SAN-903 and is ready to start the regulatory process for entering phase I trials either alone or together with a partner. SAN-903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel KCa3.1.
Compelling testimony from parents who saw life-altering changes in their children who participated in Levo Therapeutics Inc.’s intranasal carbetocin clinical trial wasn’t enough to counter what the FDA’s Psychopharmacologic Drugs Advisory Committee saw as a lack of “substantial evidence” to support the drug’s effectiveness in treating hyperphagia associated with Prader-Willi syndrome (PWS).
The regulatory path for Saniona AB’s Tesomet for treating two rare eating disorders, Prader-Willi syndrome (PWS) and hypothalamic obesity, continues to be a winding one with surprises along the way. The newest twist is pre-IND feedback from the FDA that knocked the stock down 10.5% on Oct. 9.
Soleno Therapeutics Inc.’s phase III DESTINY PWS (C601) trial evaluating once-daily diazoxide choline controlled-release tablets for treating patients with Prader-Willi syndrome (PWS) missed its primary endpoint of change from baseline in hyperphagia, or insatiable hunger, which is the disease’s predominant syndrome.